TORONTO, ONTARIO--(Marketwired - Oct. 5, 2015) - Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE:HEM), a clinical-stage autologous cell-therapy company, announced today that Dr. Rahul Sarugaser, vice president of corporate development, will present at the annual Partnering Forum, part of the 2015 Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California. Dr. Sarugaser's presentation will focus on the Hemostemix lead product ACP-01 and its international, multicenter, phase-2 clinical trial for patients with critical limb ischemia (CLI).
Cohosted by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM), and the Sanford Consortium for Regenerative Medicine, the 2015 Stem Cell Meeting on the Mesa is a three-day conference featuring a two-day Partnering Forum, a Public Forum lecture, and a full-day Scientific Symposium. It is the sector's premiere event bringing together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures.
At the Partnering Forum, held October 7 and 8, industry executives will lead in-depth, interactive panels and workshops to discuss critical commercial issues facing the sector today. The nationally recognized Scientific Symposium, held October 9 at the Salk Institute for Biological Studies, will showcase leading academic research in the field of regenerative medicine and advanced therapies.
The 2015 Stem Cell Meeting on the Mesa is expected to attract nearly 800 attendees, including leading cell-therapy, gene-therapy, and tissue-engineering companies, large pharma and biotech, industry investors, and major academic research institutions.
The following are specific details regarding Dr. Sarugaser's presentation:
|Event:||2015 Stem Cell Meeting on the Mesa-Partnering Forum|
|Date and Time:||October 7, 2:30 p.m. PDT|
|Location:||La Jolla Ballroom 2|
|Estancia La Jolla Hotel & Spa|
|9700 North Torrey Pines Road|
|La Jolla, CA 92037|
A live video webcast of all company presentations will be available at stemcellmeetingonthemesa.com/webcast and will also be published on ARM's website shortly after the event. For more information about the conference, visit stemcellmeetingonthemesa.com.
Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company to test a stem-cell therapy in an international, multicenter, phase-2 clinical trial for patients with critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The phase-2 trial targets a participant's diseased tissue with proprietary cells that are grown from his or her blood and capable of supporting the formation of new blood vessels. Hemostemix currently enrolls participants in the phase-2 trial at four sites in South Africa and two sites in Canada.
Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.